Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

類似資料

• Proteomic profiling in plasma cell disorders: A feasibility study
  著者:: Mailankody, Sham, 等
  出版事項: (2016)
• Minimal residual disease in multiple myeloma: bringing the bench to the bedside
  著者:: Mailankody, Sham, 等
  出版事項: (2015)
• Upfront Use of Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) for Stem Cell Mobilization in Patients with Multiple Myeloma: Efficacy and Analysis of Risk Factors Associated with Poor Stem Cell Collection Efficiency
  著者:: Ogunniyi, Adebayo, 等
  出版事項: (2016)
• Predictive biomarkers and practical considerations in the management of carflizomib-associated cardiotoxity
  著者:: Lendvai, Nikoletta, 等
  出版事項: (2018)
• Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood
  著者:: Murata, Kazunori, 等
  出版事項: (2016)